However, recent studies have shown that GIPR-GLP1R co-agonists or GIPR-GLP1R unimolecular agonists are unexpectedly more effective anti-hyperglycemic and anti-obesity agents compared to GLP1R agonist control [16, 17]. The gene discussed is GIPR; the disease is obesity disorder.